Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy
Backgroud: After demonstrating additional benefit versus standard of care in ARCHES and ENZAMET studies, enzalutamide was reimbursed in Italy in May 2022 by the National Health Service (NHS) for the treatment of hormone-sensitive metastatic prostate cancer (mHSPC). Objective: This study estimates t...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2023-04-01
|
| Series: | Global & Regional Health Technology Assessment |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/2507 |